Applying Synthetic Biology To Orphan Drug Development
Officially Founded in Q4 2018, After Operating in Stealth Mode For A Year
Detection, Visualization & Orphan Drug Development
Our product candidates are designed to improve detection, visualization and treatment of 3 rare diseases. We plan to file IND's, PMA's and BLA's With the US FDA to support future clinical development.
SB-101 Is designed reduce the frequency of invasive interventions in 3 rare diseases
SB-201 Is a new therapeutic paradigm in treating rare diseases of the GI tract
"Big results require big ambitions"
